GRI Bio (GRI) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GRI Bio is the larger company by market cap ($4.0 million vs $3.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | GRI | SXTC |
|---|---|---|
| Share price | $1.85 | $2.83 |
| Market cap | $4.04M | $3.74M |
| 1-day change | -2.63% | +126.40% |
| EPS (TTM) | $-14.71 | $-1,680.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $64.12 | $83,760.00 |
| 52-week low | $1.36 | $1.18 |
| Distance from 52-week high | -97.11% | -100.00% |
| Average volume | 328.06K | 3.73M |
| Shares outstanding | 2.19M | 1.32M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
GRI vs SXTC FAQ
Which is bigger, GRI Bio or China SXT Pharmaceuticals?
GRI Bio (GRI) is larger, with a market capitalization of $4.04M compared with $3.74M for China SXT Pharmaceuticals (SXTC).
Are GRI Bio and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.